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AbstrACt 
Objective To identify the key drivers of cost-effectiveness 
for cardiovascular magnetic resonance (CMR) when 
patients activate the primary percutaneous coronary 
intervention (PPCI) pathway.
Design Economic decision models for two patient 
subgroups populated from secondary sources, each with 
a 1 year time horizon from the perspective of the National 
Health Service (NHS) and personal social services in the 
UK.
setting Usual care (with or without CMR) in the NHS.
Participants Patients who activated the PPCI pathway, 
and for Model 1: underwent an emergency coronary 
angiogram and PPCI, and were found to have multivessel 
coronary artery disease. For Model 2: underwent an 
emergency coronary angiogram and were found to have 
unobstructed coronary arteries.
Interventions Model 1 (multivessel disease) compared 
two different ischaemia testing methods, CMR or fractional 
flow reserve (FFR), versus stress echocardiography. Model 
2 (unobstructed arteries) compared CMR with standard 
echocardiography versus standard echocardiography 
alone.
Main outcome measures Key drivers of cost-
effectiveness for CMR, incremental costs and quality-
adjusted life years (QALYs) and incremental cost-
effectiveness ratios.
results In both models, the incremental costs and 
QALYs between CMR (or FFR, Model 1) versus no 
CMR (stress echocardiography, Model 1 and standard 
echocardiography, Model 2) were small (CMR: −£64 (95% 
CI −£232 to £187)/FFR: £360 (95% CI −£116 to £844) and 
CMR/FFR: 0.0012 QALYs (95% CI −0.0076 to 0.0093)) and 
(£98 (95% CI −£199 to £488) and 0.0005 QALYs (95% CI 
−0.0050 to 0.0077)), respectively. The diagnostic accuracy 
of the tests was the key driver of cost-effectiveness for 
both patient groups.
Conclusions If CMR were introduced for all subgroups 
of patients who activate the PPCI pathway, it is likely 
that diagnostic accuracy would be a key determinant 
of its cost-effectiveness. Further research is needed to 
definitively answer whether revascularisation guided by 
CMR or FFR leads to different clinical outcomes in acute 
coronary syndrome patients with multivessel disease.
IntrODuCtIOn
Patients with acute coronary syndrome (ACS) 
and suspected acute thrombotic coronary 
occlusion activate the primary percutaneous 
coronary intervention (PPCI) pathway. In the 
UK National Health Service (NHS), PPCI is 
the main clinical approach to restore blood 
flow in the infarcted artery after ST-eleva-
tion myocardial infarction (STEMI).1 Many 
patients presenting to hospital with STEMI 
have multivessel disease (40%–65%),2–7 
strengths and limitations of this study
 ► We present the first cost-effectiveness analysis of 
cardiovascular magnetic resonance (CMR) and frac-
tional flow reserve (FFR) ischaemia tests compared 
with stress echocardiography in patients who acti-
vate the primary percutaneous coronary intervention 
(PPCI) pathway and are found to have multivessel 
coronary disease, and the first cost-effectiveness 
analysis of introducing CMR in patients who activate 
the PPCI pathway and are found to have unobstruct-
ed coronary arteries.
 ► This work draws on all available evidence in this 
field to provide guidance on the key drivers of 
cost-effectiveness for future research.
 ► The majority of model parameter estimates were 
based on single studies with small sample sizes, 
conducted outside the UK where patient pathways 
differ.
 ► CMR and FFR tests were treated as reference stan-
dards (assumed 100% sensitivity and specificity) in 
base-case analyses; sensitivity analyses show that 
relative cost-effectiveness varies substantially de-
pending on assumptions about these parameters.
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which may require secondary revascularisation of the 
patients’ non-infarcted territories. In addition, 3%–16% 
of patients who activate the PPCI pathway do not receive 
PPCI because angiography sometimes shows that the 
coronary arteries are unobstructed.8 9 These factors 
result in considerable uncertainty and sometimes a lack 
of a definitive diagnosis of myocardial infarction (MI) in 
these patients, which can lead to inappropriate clinical 
management,10 11 which may in turn be associated with 
poor prognosis or unnecessary resource use.12 
Cardiovascular magnetic resonance (CMR) is a non-in-
vasive imaging technique that assesses heart structure 
with high temporal resolution and can help inform 
management decisions for patients with ACS who acti-
vate the PPCI pathway. CMR can facilitate differential 
diagnosis in the context of a normal coronary angio-
gram,13–15 providing a definitive diagnosis in 65%–90% of 
patients.13 16 17 The benefits of CMR in other subgroups 
of PPCI patients, such as those found to have multivessel 
disease, are less clear. Long-term outcome data and 
studies reporting the cost-effectiveness of CMR are 
absent, further complicating resource allocation of CMR 
services within the NHS. Despite a lack of evidence, CMR 
has been increasingly used in patients with ACS in the 
UK18 and is included in the 2017 European Society of 
Cardiology guidelines on the management of patients 
presenting with STEMI.19
There has also been a rapid increase in the use of 
fractional flow reserve (FFR) testing: a guide wire-based 
procedure which is undertaken through a standard 
guide catheter during invasive angiography to assess the 
degree of ischaemia in stenosed coronary arteries. Stress 
CMR is considered to have excellent diagnostic accuracy 
compared with FFR for detecting ischaemia.20 21 The 
main benefit of ischaemia testing using FFR is that lesions 
can be assessed and revascularised in the same session; 
however, if revascularisation is not required, then the 
benefit of FFR over CMR is less clear. In addition to CMR 
and FFR, stress echocardiography (ECHO) and myocar-
dial perfusion scintigraphy using single photon emission 
CT are often used to evaluate patients with multivessel 
disease for residual ischaemia of bystander disease 
after PPCI for STEMI; stress ECHO is one of the most 
commonly used imaging modalities in the UK.22
In this paper, we present a health economic anal-
ysis based on a study that was designed to establish the 
feasibility of setting up a UK multicentre registry to 
document CMR use in patients who activate the PPCI 
pathway and determine its prognostic value and impact 
on patient management.23 Here, we present the results 
of two economic decision models which we designed to 
compare the cost-effectiveness of introducing CMR in 
two patient subgroups: patients with multivessel disease 
and those with unobstructed coronary arteries. The aim 
was to identify how the results of the analyses change in 
response to sensitivity analyses to determine key drivers 
of cost-effectiveness that could be considered for detailed 
measurement in any future research.
MethODs
Overview and treatment strategies
We built two separate cost-effectiveness models in consul-
tation with clinical experts to estimate the healthcare 
costs and quality-adjusted life years (QALYs) of intro-
ducing CMR after PPCI pathway activation in two patient 
subgroups over a 1 year time horizon:
1. Model 1 compares two types of ischaemia testing: CMR 
or FFR to stress ECHO in patients with multivessel dis-
ease (commonly defined as stenosis >50%) after index 
angiogram and PPCI.
2. Model 2 compares CMR in addition to standard ECHO 
to standard ECHO alone in patients with unobstructed 
coronary arteries after index angiogram.
Given the focus on the immediate consequences on 
clinical management of introducing additional diagnostic 
testing, and because this is a feasibility study assessing key 
drivers of cost-effectiveness rather than cost-effectiveness 
per se, we chose a 1 year time horizon. Survival to 12 
months under each testing strategy was assessed to deter-
mine whether there were differences, which would iden-
tify a need to consider a longer time horizon. From these 
two models, it may be possible to make inferences about 
the likely drivers of cost-effectiveness of introducing 
CMR for all subgroups of patients who activate the PPCI 
pathway. The analysis was conducted from an NHS and 
personal social services perspective in the UK.24
Model structure
Model 1: multivessel disease
Model 1 uses a decision tree structure (figure 1) to 
compare the cost-effectiveness of two types of ischaemia 
testing (CMR and FFR) to stress ECHO. All three tests 
are used to guide decisions regarding secondary revas-
cularisation in patients with multivessel disease. Based 
on the findings of their emergency index angiogram at 
which the culprit lesion is treated, patients can enter one 
of three test/treatment pathways to determine whether 
further treatment is required for non-culprit lesions at 
a later date: no ischaemia testing and secondary revas-
cularisation; ischaemia testing to guide decisions for 
secondary revascularisation or no ischaemia testing 
and no secondary revascularisation. Patients are then 
divided into whether they ‘truly’ have ischaemia or not. 
For patients receiving ischaemia testing, the test results 
can be either positive or negative (ischaemia present or 
not), and the model reflects potential misclassification of 
patients (ie, ischaemia testing has a sensitivity and speci-
ficity). Patients entering any of the three test/treatment 
pathways are then at risk of experiencing a major adverse 
cardiovascular event (MACE) or no MACE over the 1 year 
time horizon. MACE is a composite endpoint of all-cause 
mortality, MI, stroke or (repeat) revascularisation.
The model structure is the same for the three ischaemia 
testing options, but there are differences in the timing 
of testing and secondary revascularisation between these 
arms (note for all arms this testing and secondary revas-
cularisation, if required, is at a later date than the index 
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angiogram at PPCI and treatment of the culprit lesion). 
For CMR and stress ECHO, this is a two-step process (ie, 
a patient has the ischaemia test and then separately has 
secondary revascularisation). For FFR, this happens at the 
same time (ie, a patient has their diagnostic angiogram 
and FFR, and if required, secondary revascularisation). 
We have assumed that this timing difference only affects 
costs, but not the model structure.
Model 2: unobstructed coronary arteries
Model 2 also uses a decision tree structure (figure 2) to 
compare the cost-effectiveness of CMR with standard 
ECHO to ‘current practice’ of standard ECHO only. 
These tests are used to guide decisions in offering treat-
ment for MI in patients who activate the PPCI pathway but 
are found to have unobstructed coronary arteries. In each 
arm, patients are divided according to whether they truly 
Figure 1 Model 1 structure—patients with multivessel disease. Patient pathways for FFR and stress ECHO are identical to 
those for CMR. CMR, cardiovascular magnetic resonance; ECHO, echocardiography; FFR; fractional flow reserve; MACE, major 
adverse cardiovascular events.
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Figure 2 Model 2 structure—patients with unobstructed coronaries. CMR, cardiovascular magnetic resonance; ECHO, 
echocardiography; MACE, major adverse cardiovascular events; MI, myocardial infarction.
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had an MI or not. Results for both testing approaches can 
be either positive or negative (MI occurred or not), with 
the model again reflecting the potential for misclassifica-
tion. Patients receiving a positive test result are assumed 
to have had an MI and receive treatment (cardiac reha-
bilitation and medications). A negative test results in 
treatment for other cardiac causes of chest pain (fewer 
cardiac medications or none at all). Thereafter, patients 
are divided into whether they had MACE or not over the 
1 year time horizon.
economic analyses
TreeAge Pro 2013 (TreeAge Software, Williamstown, 
Massachusetts, USA) was used to develop and analyse 
the models. Resources were valued in 2015/2016 pounds 
sterling. The expected costs and QALYs associated with 
each testing strategy to 1 year were calculated. Costs and 
QALYs were not discounted, as the time horizon was only 
1 year. Incremental cost-effectiveness ratios (ICERs) were 
calculated as the ratio of the difference in cost to the 
difference in QALYs between each testing option and its 
comparator.
Identification of model parameters
Testing and clinical parameters used in both models were 
derived from reviews of the literature. Unit costs were 
obtained from standard UK sources, notably the National 
Schedule of Reference Costs and the British National 
Formulary.25 26 Health state utility values were identified 
by searching the Tufts Cost-effectiveness Analysis (CEA) 
Registry.27
For model 1, we searched Medline using Medical 
Subject Headings and keywords for each ischaemia test 
(eg, exp/pressure-wire or  pressure- wire. mp or frac-
tional flow  reserve. mp and exp/myocardial infarction). 
Review articles, reference lists and citations of relevant 
studies were also evaluated. For model 2, initial Medline 
searching identified a 2016 review paper,28 which refer-
enced the inaugural study of CMR in patients with unob-
structed coronary arteries.13 All citations of this primary 
paper were reviewed.13 Two meta-analyses were identified 
and their citations were reviewed.29 30 Medline was also 
searched using keywords such as ‘myocardial infarction 
with non-obstructive coronary arteries’ and synonyms.
Complete lists of model parameters, their respective 
sources and assumptions made in their estimation are 
provided in online supplementary appendices A and B 
and briefly summarised below.
testing parameters
Model 1: multivessel disease
CMR and FFR were treated as reference standards with 
assumed 100% sensitivity and specificity. While FFR is the 
reference standard for detecting ischaemia in patients 
with stable coronary artery disease, there is uncertainty 
in how FFR-guided revascularisation influences outcome 
in this high-risk group of STEMI patients with multivessel 
disease. It was therefore considered a reasonable 
base-case assumption that the sensitivities and specifici-
ties of CMR and FFR were the same in this population. 
While in practice their sensitivity and specificity are likely 
to be a little less than 100%, there is no gold standard test 
for ischaemia in STEMI patients with multivessel disease 
with which to compare; lower sensitivities and specificities 
were explored in sensitivity analyses. The assumption of 
100% sensitivity and specificity for CMR and FFR results 
in identical probabilities and outcomes, but differences 
in costs for the two arms. Sensitivity and specificity values 
for stress ECHO were obtained from Gurunathan et al.31
Model 2: unobstructed coronary arteries
CMR with standard ECHO was treated as a reference stan-
dard, whereas sensitivity and specificity values for stan-
dard ECHO were obtained from Dastidar et al.32
Clinical parameters
Model 1: multivessel disease
The probabilities of patients entering one of the three 
test/treatment pathways were based on expert clinical 
opinion. Probabilities of true ischaemia for each test/
treatment pathway were derived from the FAME study.33 
Subgroup outcomes from Smits et al were used to estimate 
probabilities of MACE for three patient groups: truly isch-
aemic patients who had secondary revascularisation, truly 
ischaemic patients who did not have secondary revascu-
larisation and truly non-ischaemic patients, regardless of 
secondary revascularisation.34
Model 2: unobstructed coronary arteries
Studies reporting the probability of MACE in patients with 
unobstructed coronary arteries have used varying defini-
tions of MACE and follow-up periods (12–34 months).35–38 
In patients with <50% coronary artery stenosis, Kang 
et al reported a 7.8% risk of MACE at 1 year,37 but their 
MACE definition did not include stroke. Three studies 
reported MACE, broken down by CMR diagnosis.35 36 38 
Pathik et al reported MACE for 27% of patients diagnosed 
with MI, and for 5% of patients without MI (diagnosed 
with myocarditis, cardiomyopathy or normal CMR) over a 
median of 24 months.38 In the other two studies, no MACE 
outcomes were observed in the patients without MI. The 
MACE estimates reported in Pathik et al were converted 
to continuous rates (assuming events occur evenly over 24 
months of follow-up). The ratio of events in the patients 
with MI compared with the patients without MI was 6 and 
was used with the overall estimate of MACE at 1 year from 
Kang et al (0.078),37 and the probability of patients truly 
having an MI from Pasupathy et al (0.24),29 to calculate 
the probability of MACE in patients who truly had an MI 
(0.21) and in those who did not have an MI (0.03).
The hazard ratio for MACE in patients who were taking 
statins compared with those who were not (0.77) reported 
by Lindahl et al was used to adjust the probability of 
MACE for patients who had an MI, giving a probability of 
MACE for those with MI but without treatment of 0.26.39 
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For patients without MI, the probability of MACE of 0.03 
was assumed to apply regardless of treatment.
Cost parameters
Model 1: multivessel disease
The costs considered for all three ischaemia testing strat-
egies included: the cost of ischaemia testing (CMR, FFR 
or stress ECHO) if required, secondary revascularisation, 
adverse events included in MACE (initial inpatient and 
postdischarge costs), medications and cardiac rehabilita-
tion offered to all patients and additional healthcare costs 
beyond hospital discharge to 1 year, including follow-up 
outpatient appointments.
Model 2: unobstructed coronary arteries
The costs considered for the two testing strategies 
included: the cost of testing (CMR and/or standard 
ECHO), cardiac rehabilitation and medications for 
patients classified as either having had an MI or a non-MI 
diagnosis (details in online supplementary appendix B), 
adverse events included in MACE (initial inpatient and 
postdischarge costs) and additional healthcare costs 
beyond hospital discharge to 1 year, including a follow-up 
appointment.
Quality-adjusted life years
Model 1: multivessel disease
QALYs were estimated over 1 year as a function of survival 
and health state utility values. Since death is one of the 
components of MACE, we assumed that patients without 
MACE are all alive at 1 year and that the probability of 
dying for MACE patients was 0.08 as estimated by Smits 
et al.34 We identified mean utility values of 0.72, 0.77 and 
0.77 at baseline (during index hospitalisation), 1 and 
12 months, respectively, estimated using the UK EQ-5D-3L 
tariff in patients with STEMI having PPCI.27 40
QALYs were calculated assuming a patient’s utility 
changed linearly between each time point or death. 
Patients who died were assumed to die midway through 
the time-period (6 months) and have a utility of zero after 
death. QALYs for patients without MACE who were all 
alive at 1 year were calculated based on the utility values 
for the three time-points above.40 QALYs for patients 
with MACE were also calculated using these three utility 
values, but assuming 8% of patients died to produce a 
weighted average for patients alive and dead at 1 year.34 
A utility decrement of 0.05 was applied to this weighted 
average to reflect the reduced quality-of-life of patients 
with MACE compared with those without.41 QALYs for 
patients who had secondary revascularisation were modi-
fied to assume their utility at the 1 month time-point was 
repeated for a subsequent month.
Model 2: unobstructed coronary arteries
Searches of the CEA Registry did not yield any utility 
values for patients with unobstructed coronary arteries, 
and therefore QALYs for patients with and without MACE 
in model 2 were calculated using the same utility values 
and methods as for model 1.40
base-case and sensitivity analyses
The best available point estimates were used in the base-
case analyses in which ICERs were the summary measures. 
Since this was a feasibility study, the actual ICERs are not 
the main interest, but rather how they change in response 
to sensitivity analyses.
One-way deterministic sensitivity analyses (DSAs) 
were conducted to test the impact of varying the base-
case values for several model parameters. Alternative 
values for DSAs (online supplementary appendices 
C and D) were obtained from substitute evidence 
sources, clinical judgement (eg, 8% probability of 
death for patients with MACE was thought to be low, 
and a relative risk of 6 to be high for events in patients 
with MI compared with patients without MI, so higher 
and lower values were explored) or altering mean 
values for unit costs by ±20%. Threshold analyses were 
also conducted to establish the cost of each test at 
which the expected costs associated with an alternative 
strategy would be identical.
Probabilistic sensitivity analyses (PSAs) were used to 
account for the impact on results of all uncertain param-
eters simultaneously. Parameters were assigned distribu-
tions based on the precision of estimates available to 
describe a range of plausible values, and 1000 randomly 
selected values from each distribution were generated 
and results calculated for each run of the model. 95% 
CI and scatter plots of the 1000 incremental costs and 
QALYs for each comparison were then assessed.
Patient and public involvement
Patients and the public were not involved in the design 
of this study.
results
base-case results
Model 1: multivessel disease
Over 1 year, the expected total costs of stress ECHO, CMR 
and FFR strategies per patient were £5495, £5431 and 
£5855, respectively (table 1). Use of stress ECHO produced 
0.7564 QALYs, whereas CMR and FFR both resulted in an 
additional 0.0012 QALYs gained. CMR dominated stress 
ECHO as a CMR strategy was less costly (–£64) and more 
effective (+0.0012 QALYs). FFR was more costly (£360) 
and more effective (+0.0012 QALYs) than stress ECHO, 
resulting in an ICER above the accepted cost-effectiveness 
threshold of £20 000–£30 000 per QALY.
Model 2: unobstructed coronary arteries
Over 1 year, the expected total costs of CMR with standard 
ECHO and standard ECHO alone strategies per patient 
were £3130 and £3032, respectively (table 2). Use of CMR 
with standard ECHO produced 0.0005 more QALYs than 
standard ECHO alone, at an increase in costs of £98, 
resulting in an ICER above the accepted cost-effectiveness 
threshold.
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sensitivity analyses
Model 1: multivessel disease
Table 1 reports the results of the DSAs for model 1. DSA 
1, varying the probabilities of a clinician ordering an isch-
aemia test and of a decision to perform a secondary revas-
cularisation (or not), affects the mean costs and QALYs 
under each strategy but does not alter the cost-effective-
ness results. When the specificity, or sensitivity and speci-
ficity of CMR were reduced to 80% (DSA 2), CMR became 
more costly than stress ECHO, rather than dominant, and 
at accepted cost-effectiveness thresholds, would not be 
considered cost-effective relative to stress ECHO. When 
the sensitivity and/or specificity of FFR were reduced to 
80% (DSA 3), conclusions did not alter, but the ICER 
increased. In DSA 4, using higher sensitivity, or sensitivity 
and specificity values for stress ECHO, the ICER for CMR 
would still be considered cost-effective but when using a 
higher specificity only for stress ECHO, CMR would no 
longer be considered cost-effective. Improved sensitivity 
and/or specificity for stress ECHO resulted in an even 
more unfavourable ICER for FFR. Altering the proba-
bility of MACE (DSA 5), the costs of the ischaemia tests 
(DSAs 6 and 7), and QALYs for patients with and without 
MACE (DSAs 8 and 9), did not alter cost-effectiveness 
conclusions.
Threshold analyses identified that if the cost of CMR 
increased to £371 (from a base-case value of £264), there 
would be no difference in the expected costs of the CMR 
and stress ECHO strategies. Similarly, the cost of angio-
gram and FFR would need to be reduced to £250 and 
£415 (from a base-case value of £1340) for there to be no 
difference in the expected costs of CMR and stress ECHO 
strategies, respectively compared with FFR.
The 1000 simulated incremental costs and QALYs from 
the PSA (figure 3A and B) show considerable uncertainty 
in the base-case results. This uncertainty is apparent in 
both figures as the spread of estimates crosses two or 
three quadrants of the cost-effectiveness plane.
Under all testing strategies, the probability of survival to 
12 months was 0.99. If a cohort of 1000 patients entered 
each strategy, on average there would be one more death 
by 12 months under a stress ECHO strategy compared 
with CMR/FFR (11 vs 10 deaths). Given that there is no 
difference in survival, we did not extrapolate findings to a 
longer time horizon.
Model 2: unobstructed coronary arteries
Table 2 reports the results of the DSAs for model 2. 
Reducing the diagnostic accuracy of CMR (DSA 1), 
increasing the diagnostic accuracy of standard ECHO 
(DSA 2) and increasing the cost of CMR (DSA 6) had the 
greatest impact on the mean incremental cost between 
CMR with standard ECHO and standard ECHO alone. 
Altering QALYs (DSAs 8, 9 and 10), had the greatest 
impact on the mean incremental QALYs between the 
arms. However, in all DSAs conducted, CMR with stan-
dard ECHO remained both more costly and more effec-
tive than standard ECHO alone, resulting in ICERs that 
were consistently above the accepted cost-effectiveness 
threshold.
Threshold analyses show that if the cost of CMR reduced 
to £166 (from a base-case value of £264), there would be 
no difference in the expected costs between strategies.
Similar to model 1, the 1000 simulated incremental 
costs and QALYs (figure 3C) indicate considerable uncer-
tainty in the base-case results; again, the estimates are 
spread across three quadrants of the cost-effectiveness 
plane.
Under both strategies, the probability of survival to 
12 months was 0.99. If a cohort of 1000 patients entered 
each strategy, on average there would be one more death 
by 12 months under a standard ECHO strategy compared 
with standard ECHO and CMR (seven vs six deaths). As 
for model 1, given that there is no difference in survival, 
we did not extrapolate findings to a longer time horizon.
DIsCussIOn
We developed economic decision models to identify 
key drivers of cost-effectiveness of CMR compared with 
‘current practice’ in two subgroups of patients who acti-
vate the PPCI pathway: multivessel disease (model 1) and 
unobstructed coronary arteries (model 2). ‘Current prac-
tice’ for ischaemia testing in multivessel disease varies 
widely. The results of both models suggest that differences 
in QALYs between strategies are small and, therefore, the 
results are largely driven by modest differences in costs.
In model 1, only 35% of patients receiving ischaemia 
testing truly had ischaemia, therefore the majority of 
patients received an expensive test without needing 
further treatment. If more patients needed revascu-
larisation, the expected cost of the FFR strategy would 
reduce as potential economies of scale would result from 
performing the ischaemia test and secondary revascular-
isation concurrently. In model 2, the reduction in costs 
associated with treating fewer patients for MI if CMR were 
to be introduced only partially compensated for the addi-
tional cost of CMR. DSAs for both models identified the 
diagnostic accuracy of the tests as the key driver of cost-ef-
fectiveness. In model 1, the costs of ischaemia testing and 
QALYs associated with MACE/no MACE also influenced 
cost-effectiveness, but the latter factors had minimal 
impact compared with altering the diagnostic accuracy of 
CMR and FFR. For model 2, the cost of CMR, the QALYs 
associated with MACE/no MACE, and the proportion of 
patients with MACE who die, influenced cost-effective-
ness results.
Overall, we have identified the sensitivity and speci-
ficity of the tests as the key drivers of cost-effectiveness 
in both models. It is likely that any business case to intro-
duce CMR for all patients who activate the PPCI pathway 
would require accurate estimates of these parameters to 
be collected in future studies.
In terms of limitations of our study, first, many parameter 
estimates were obtained from a single study conducted 
outside the UK, where practices may differ. Estimates 
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Figure 3 (A) Model 1: plot of the 1000 simulated cost and QALY differences from the PSA for CMR versus stress ECHO. (B) 
Model 1: plot of the 1000 simulated cost and QALY differences from the PSA for FFR versus stress ECHO. (C) Model 2: plot 
of the 1000 simulated cost and QALY differences from the PSA for standard ECHO and CMR versus standard ECHO. CMR, 
cardiovascular magnetic resonance; ECHO, echocardiography; FFR; fractional flow reserve; PSA, probabilistic sensitivity 
analyses; QALY, quality-adjusted life year.
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from different patient groups were sometimes used to 
populate the model. For example, in model 1, the diag-
nostic accuracy of stress ECHO was derived from a study 
diagnosing significant coronary artery disease, rather 
than PPCI patients.31 Despite these potential limitations, 
our model represents the best available evidence.
Second, for the base-case analysis of model 1, CMR and 
FFR were treated as reference standards, assuming 100% 
sensitivity and specificity. We considered identical values 
for CMR and FFR as a reasonable starting point, while 
FFR is the reference standard for detecting ischaemia in 
patients with stable coronary artery disease, there is uncer-
tainty in whether this also applies to a STEMI population 
with multivessel disease. There is no gold standard test 
for ischaemia in this population with which to compare. 
However, it is important to note that varying the sensitivity 
and specificity in DSAs for model 1 had large impacts on 
cost-effectiveness results. Similarly, for model 2, reducing 
the diagnostic accuracy of CMR with standard ECHO 
compared with standard ECHO doubled the ICER.
Third, resource use was estimated for patients in both 
models based on standard patient pathways described by 
clinical experts, as individual patient data from routine 
sources (eg, Hospital Episode Statistics) were not avail-
able at the time of analysis. This may underestimate the 
variability between individual patients.
Finally, there was uncertainty around the utility decre-
ment of 0.05 for patients with MACE compared with those 
without MACE.41 Although this decrement has been used 
by others, it is not based on primary data.42 In addition, 
utility estimates for patients with unobstructed coronary 
arteries were not available requiring the use of utility 
estimates from a population with STEMI having PPCI in 
model 2. We considered these assumptions to be reason-
able given (1) quality-of-life using the Short Form-36 was 
similar for patients with unobstructed coronary arteries 
and a control group of patients with MI with coronary 
heart disease43 and (2) we varied QALYs in the DSAs.
Our cost-effectiveness models have highlighted that 
the diagnostic accuracies of the tests (CMR and FFR, 
and CMR) are key drivers of the relative cost-effective-
ness of management strategies based on these tests 
when compared with ‘current practice’ for patients 
with multivessel disease and unobstructed coronaries, 
respectively. In the base-case analyses for patients with 
multivessel disease, FFR was not cost-effective relative to 
stress ECHO and was more costly than a CMR strategy. 
For patients with stable angina, the MR-INFORM trial 
showed that CMR-guided management is non-inferior 
for MACE at 1 year compared with invasive angiography 
and FFR.44 It is, therefore, concerning that there has been 
rapid adoption of FFR for detecting ischaemia during our 
study despite a lack of evidence of benefit over CMR; this 
may reflect the lack of capacity for CMR nationally. Future 
research should seek to quantify the relative diagnostic 
accuracy of CMR and FFR compared with stress ECHO 
and versus each other. The fact that both CMR and FFR 
testing are regarded as reference standards in clinical 
practice and no superior standard is recognised may 
mean that the cost-effectiveness of CMR compared with 
FFR can only be tested in a randomised controlled trial, 
in which the impact of the ischaemia tests on patients’ 
care pathways could be directly observed.
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